Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00285467|
Recruitment Status : Completed
First Posted : February 2, 2006
Results First Posted : May 2, 2016
Last Update Posted : May 2, 2016
|Condition or disease||Intervention/treatment||Phase|
|Renal Osteodystrophy||Drug: doxercalciferol Drug: Cholecalciferol||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||55 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
form of vitamin D that is already in active form.
Other Name: Hectoral
Active Comparator: Cholecalciferol
cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
from of vitamin D that requires cells in the body to make active
Other Name: vitamin D3
- Percent Reduction in PTH [ Time Frame: 3 month ]Percent reduction in PTH from baseline to 3 months
- Systolic Blood Pressure at 3 Months [ Time Frame: 3 month ]systolic blood pressure at 3 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285467
|United States, Indiana|
|Indiana University School of Medicine|
|Indianapolis, Indiana, United States, 46202|
|Study Director:||Sharon Moe, MD||Indiana University School of Medicine|